Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738553 · ClinicalTrials.gov registry record
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
A clinical trial of HER2-positive Breast Cancer, sponsored by University of Washington.
- Active
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT03738553 is a study of HER2-positive Breast Cancer that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 13 participants, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03738553, a study of HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DEVICE MRI
Study Locations (1)
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-08 |
| Est. Completion | 2026-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738553
The ClinicalTrials.gov registry entry for NCT03738553 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 54 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Trastuzumab is the first listed.
NCT03738553 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT03738553 about?
NCT03738553 is a clinical study titled "Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy". This is a single institution, observational research study in which patients are observed using DWI/DCE MRI imaging before and after receiving neoadjuvant anti-HER2 therapy.
What is the current status of trial NCT03738553?
This trial is currently active not recruiting. The enrollment target is 13 participants. The study started on 2013-08. Estimated completion is 2026-03.
What conditions does trial NCT03738553 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT03738553?
The interventions under investigation include: Trastuzumab (DRUG), MRI (DEVICE).
Who is sponsoring clinical trial NCT03738553?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03738553 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
-
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
RECRUITING · Phase 2
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RECRUITING · Phase 1
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.